General demographics | Â | Â | Â |
---|---|---|---|
 | Males (n= 70) | Females (n= 174) | Total |
   Physical activity (MET-minutes/week) | 1,674.5 (982.5 to 2,479.2) | 1,470.0 (993.0 to 2,082.5) | 1,550 (989.5 to 2,175.0) |
   Age (years) | 62.1 (55.8 to 68.7) | 62.3 (52.8 to 70.2) | 62.1 (53.8 to 69.4) |
   Smoking status |  |  |  |
   current smokers n (%) | 14 (20.9%) | 31 (18.1%) | 45 (18.9%) |
Anthropometric | Â | Â | Â |
   Height (cm) | 172.9 ± 7.1 | 160.7 ± 6.9* | 164.2 ± 8.8 |
   Weight (kg) | 81.7 (73.1 to 93.0) | 70.8 (61.6 to 81.3)** | 73.8 (64.9 to 84.0) |
   Body Mass Index (kg/m2) | 27.1 (25.0 to 30.3) | 26.7 (24.1 to 31.7) | 27.0 (24.4 to 30.8) |
   Fat-free mass (kg) | 58.6 (53.1 to 65.4) | 43.4 (39.1 to 46.9)** | 45.9 (41.4 to 53.1) |
   Fat mass (%) | 28.6 (22.2 to 31.8 | 38.8 (34.6 to 43.1)** | 36.2 (29.7 to 40.8) |
RA characteristics | Â | Â | Â |
General characteristics | Â | Â | Â |
   Rheumatoid factor positive n (%) | 45 (72.6%) | 118 (77.1%) | 163 (75.8%) |
   Disease duration (years) | 9.0 (3.5 to 18.0) | 11.0 (4.0 to 20.0) | 11.0 (4.0 to 19.0) |
Disease activity | Â | Â | Â |
   C-Reactive protein (mg/L) | 11.5 (6.0 to 22.2) | 8.0 (5.0 to 20.0) | 9.0 (5.0 to 21.0) |
   ESR (mm/1 hr) | 23.0 (5.0 to 39.0) | 22.0 (12.2 to 39.0) | 23.0 (10.0 to 39.0) |
   Disease activity score 28 | 4.3 ± 1.4 | 4.2 ± 1.5 | 4.2 ± 1.4 |
Disability | Â | Â | Â |
   Health assessment Questionnaire | 1.2 (0.5 to 2.1) | 1.5 (0.5 to 2.1) | 1.5 (0.5 to 2.1) |
Medication | Â | Â | Â |
   DMARDs n (%) | 65 (92.9%) | 144 (83.2%)* | 209 (86%) |
   Methotrexate n (%) | 41 (58.6%) | 95 (54.9%) | 136 (56%) |
   antiTNFα n (%) | 6 (8.6%) | 24 (13.9%) | 30 (12.3%) |
   leflunomide n (%) | 1 (1.4%) | 10 (5.8%) | 11 (4.5%) |
   prednisolone n (%) | 30 (42.9%) | 51 (29.5%) | 81 (33.3%) |
   NSAID n (%) | 16 (22.9%) | 30 (17.3%) | 46 (18.9%) |
   Cholesterol-lowering n (%) | 16 (22.9%) | 28 (16.2%) | 44 (18.1%) |